Q-omics provides the consensus-scored MT1P3 profile across patient tissues and cancer cell-line models. MT1P3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MT1P3 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MT1P3 RNA expression shows 6,003 significant pathway-activity associations, with the highest sampling consensus in LGG. Together, these results highlight LGG, and LIHC as cancer lineages where MT1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1P3 survival associations across molecular data types. MT1P3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1P3 RNA expression–survival associations across cancer types. High MT1P3 expression shows unfavorable associations in LGG, UCEC and UCS, but favorable associations in LUAD, CESC and SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MT1P3 RNA expression.
This table summarizes MT1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MT1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1P3 shows lower tumor expression in LIHC, BRCA, THCA, COAD, READ and LUSC. The LIHC box plot shows higher MT1P3 RNA expression in normal versus tumor tissue (log2 FC = −2.042, t-test p < 0.001).
This table shows molecular features associated with MT1P3 in patient tissues and cancer cell lines. In patient samples, MT1P3 shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set.
